These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35156893)

  • 1. Changes in colonic enteroendocrine cells of patients with irritable bowel syndrome following fecal microbiota transplantation.
    Mazzawi T; Hausken T; El-Salhy M
    Scand J Gastroenterol; 2022 Jul; 57(7):792-796. PubMed ID: 35156893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.
    Mazzawi T; El-Salhy M; Lied GA; Hausken T
    Front Cell Infect Microbiol; 2021; 11():524851. PubMed ID: 34055657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.
    Halkjær SI; Christensen AH; Lo BZS; Browne PD; Günther S; Hansen LH; Petersen AM
    Gut; 2018 Dec; 67(12):2107-2115. PubMed ID: 29980607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engraftment of strictly anaerobic oxygen-sensitive bacteria in irritable bowel syndrome patients following fecal microbiota transplantation does not improve symptoms.
    Browne PD; Cold F; Petersen AM; Halkjær SI; Christensen AH; Günther S; Hestbjerg Hansen L
    Gut Microbes; 2021; 13(1):1-16. PubMed ID: 34074214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
    El-Salhy M; Hatlebakk JG; Gilja OH; Bråthen Kristoffersen A; Hausken T
    Gut; 2020 May; 69(5):859-867. PubMed ID: 31852769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota.
    Huang HL; Chen HT; Luo QL; Xu HM; He J; Li YQ; Zhou YL; Yao F; Nie YQ; Zhou YJ
    J Dig Dis; 2019 Aug; 20(8):401-408. PubMed ID: 31070838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome.
    El-Salhy M; Valeur J; Hausken T; Gunnar Hatlebakk J
    Neurogastroenterol Motil; 2021 Feb; 33(2):e13983. PubMed ID: 32945066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study.
    Holster S; Lindqvist CM; Repsilber D; Salonen A; de Vos WM; König J; Brummer RJ
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00034. PubMed ID: 31009405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome.
    Goll R; Johnsen PH; Hjerde E; Diab J; Valle PC; Hilpusch F; Cavanagh JP
    Gut Microbes; 2020 Nov; 12(1):1794263. PubMed ID: 32991818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in duodenal enteroendocrine cells in patients with irritable bowel syndrome following dietary guidance.
    Mazzawi T; El-Salhy M
    Exp Biol Med (Maywood); 2017 Jul; 242(13):1355-1362. PubMed ID: 28737477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogenic Faecal Microbiota Transfer Induces Immune-Related Gene Sets in the Colon Mucosa of Patients with Irritable Bowel Syndrome.
    Holster S; Hooiveld GJ; Repsilber D; Vos WM; Brummer RJ; König J
    Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31597320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
    Mazzawi T; Hausken T; Hov JR; Valeur J; Sangnes DA; El-Salhy M; Gilja OH; Hatlebakk JG; Lied GA
    Scand J Gastroenterol; 2019 Jun; 54(6):690-699. PubMed ID: 31190584
    [No Abstract]   [Full Text] [Related]  

  • 15. The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation.
    Mazzawi T; Lied GA; Sangnes DA; El-Salhy M; Hov JR; Gilja OH; Hatlebakk JG; Hausken T
    PLoS One; 2018; 13(11):e0194904. PubMed ID: 30427836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome.
    Mizuno S; Masaoka T; Naganuma M; Kishimoto T; Kitazawa M; Kurokawa S; Nakashima M; Takeshita K; Suda W; Mimura M; Hattori M; Kanai T
    Digestion; 2017; 96(1):29-38. PubMed ID: 28628918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal microbiota transplantation in patients with irritable bowel syndrome: an overview of current studies.
    Körner E; Lorentz A
    J Appl Microbiol; 2023 Mar; 134(3):. PubMed ID: 36882216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Lahtinen P; Jalanka J; Hartikainen A; Mattila E; Hillilä M; Punkkinen J; Koskenpato J; Anttila VJ; Tillonen J; Satokari R; Arkkila P
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1321-1331. PubMed ID: 32343000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH; Hilpüsch F; Cavanagh JP; Leikanger IS; Kolstad C; Valle PC; Goll R
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan.
    Hamazaki M; Sawada T; Yamamura T; Maeda K; Mizutani Y; Ishikawa E; Furune S; Yamamoto K; Ishikawa T; Kakushima N; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Nakamura M; Fujishiro M
    BMC Gastroenterol; 2022 Jul; 22(1):342. PubMed ID: 35836115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.